{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:31:45Z","timestamp":1781530305582,"version":"3.54.1"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Doctoral Research Foundation Project of Liaoning Province","award":["2022-BS-130"],"award-info":[{"award-number":["2022-BS-130"]}]},{"name":"Shenyang Science and Technology Plan","award":["22-321-33-13"],"award-info":[{"award-number":["22-321-33-13"]}]},{"name":"the 345 Talent Project of Shengjing Hospital of China Medical University","award":["-"],"award-info":[{"award-number":["-"]}]},{"name":"the Science and Technology Department Project of Liaoning Province","award":["No. 2021JH2; No. 10300087"],"award-info":[{"award-number":["No. 2021JH2; No. 10300087"]}]},{"name":"Science Plan Program of Shenyang City","award":["21-172-9-08"],"award-info":[{"award-number":["21-172-9-08"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,20]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Nasopharyngeal carcinoma (NPC) has a poor prognosis, largely due to immune escape. The programmed cell death protein 1 (PD-1) receptor and its ligand, PD-L1, play critical roles in this immune evasion. Consequently, blocking the PD-1\/PD-L1 pathway with immune checkpoint inhibitors has become an established therapeutic strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We performed a systematic literature search of PubMed, Embase, and the Cochrane Library for studies published up to November 14, 2024, investigating PD-1\/PD-L1 inhibitors in recurrent or metastatic NPC. The analyzed outcomes included progression-free survival (PFS), overall survival (OS), 1-year PFS rate, 1-year OS rate, objective response rate, disease control rate, and adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Nine studies (comprising 10 datasets with 883 NPC patients) were included, consisting of 2 randomized controlled trials (RCTs) and 7 single-arm studies. The pooled analysis demonstrated a median PFS of 4.21 months (95% confidence interval [CI]: 2.47\u20135.95;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.000;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u200578.5%) and a median OS of 16.27 months (95% CI: 14.60\u201317.94;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.000;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u20050%). The pooled 1-year PFS rate was 43% (95% CI: 14%\u201373%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.004;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u200599.1%), and the 1-year OS rate was 80% (95% CI: 70%\u201391%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.000;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u200582.0%). The objective response rate was 45% (95% CI: 25%\u201364%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.000;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u200596.8%), and the disease control rate was 65% (95% CI: 48%\u201382%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.000;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u200596.4%). The incidence of any-grade AEs was 90% (95% CI: 74%\u201399%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.000;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u200594.1%), while grade \u22653 AEs occurred in 34% of patients (95% CI: 12%\u201361%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.001;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u200595.2%). No significant publication bias was identified.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This meta-analysis summarizes the efficacy and safety profile of PD-1\/PD-L1 inhibitors in recurrent or metastatic NPC. The findings highlight the need for additional randomized controlled trials to further validate the role of these therapies and provide an updated reference for clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000047828","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T20:00:47Z","timestamp":1774036847000},"page":"e47828","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["PD-1\/PD-L1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"105","author":[{"given":"Weiliang","family":"Bai","sequence":"first","affiliation":[{"name":"Department of Otolaryngology Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengqun","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Periodontics, School and Hospital of Stomatology, China Medical University, Shenyang, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingying","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology Head and Neck Surgery, The First People\u2019s Hospital of Horqin District, Tongliao, Inner Mongolia, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4277-5109","authenticated-orcid":false,"given":"Tiancong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260422","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0140-6736(15)00055-0","article-title":"Nasopharyngeal carcinoma.","volume":"387","author":"Chua","year":"2016","journal-title":"Lancet"},{"key":"R2-20260422","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R3-20260422","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.oraloncology.2014.02.006","article-title":"Etiological factors of nasopharyngeal carcinoma.","volume":"50","author":"Tsao","year":"2014","journal-title":"Oral Oncol"},{"key":"R5-20260422","doi-asserted-by":"crossref","first-page":"vii83","DOI":"10.1093\/annonc\/mds266","article-title":"Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"23","author":"Chan","year":"2012","journal-title":"Ann Oncol"},{"key":"R6-20260422","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/annonc\/mdy249","article-title":"Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.","volume":"29","author":"Hong","year":"2018","journal-title":"Ann Oncol"},{"key":"R7-20260422","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2019.07.007","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.","volume":"119","author":"Yang","year":"2019","journal-title":"Eur J Cancer"},{"key":"R8-20260422","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1142\/S0192415X19500629","article-title":"Application of Chinese medicine in acute and critical medical conditions.","volume":"47","author":"Luo","year":"2019","journal-title":"Am J Chin Med"},{"key":"R9-20260422","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.30566","article-title":"Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA\/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: final results of 2 parallel phase 2 clinical trials.","volume":"123","author":"Kong","year":"2017","journal-title":"Cancer"},{"key":"R10-20260422","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","article-title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.","volume":"16","author":"Al-Sarraf","year":"1998","journal-title":"J Clin Oncol"},{"key":"R11-20260422","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/jnci\/dji084","article-title":"Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma.","volume":"97","author":"Chan","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R12-20260422","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1758-3284-3-30","article-title":"Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5-fluorouracil in locally advanced nasopharyngeal carcinoma.","volume":"3","author":"Dechaphunkul","year":"2011","journal-title":"Head Neck Oncol"},{"key":"R13-20260422","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.radonc.2017.03.019","article-title":"Metastatic nasopharyngeal carcinoma: patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy.","volume":"124","author":"Rusthoven","year":"2017","journal-title":"Radiother Oncol"},{"key":"R14-20260422","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/S0140-6736(16)31388-5","article-title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.","volume":"388","author":"Zhang","year":"2016","journal-title":"Lancet"},{"key":"R15-20260422","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1200\/JCO.21.00396","article-title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma: final overall survival analysis of GEM20110714 phase III study.","volume":"39","author":"Hong","year":"2021","journal-title":"J Clin Oncol"},{"key":"R16-20260422","doi-asserted-by":"crossref","first-page":"568931","DOI":"10.3389\/fimmu.2020.568931","article-title":"The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment.","volume":"11","author":"Hudson","year":"2020","journal-title":"Front Immunol"},{"key":"R17-20260422","doi-asserted-by":"crossref","first-page":"680955","DOI":"10.3389\/fimmu.2021.680955","article-title":"Metabolic reprogramming and immune evasion in nasopharyngeal carcinoma.","volume":"12","author":"Huang","year":"2021","journal-title":"Front Immunol"},{"key":"R18-20260422","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer.","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"R19-20260422","doi-asserted-by":"crossref","first-page":"731798","DOI":"10.3389\/fphar.2021.731798","article-title":"PD-1\/PD-L1 checkpoint inhibitors in tumor immunotherapy.","volume":"12","author":"Liu","year":"2021","journal-title":"Front Pharmacol"},{"key":"R20-20260422","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial.","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"key":"R21-20260422","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","article-title":"Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.","volume":"27","author":"Mai","year":"2021","journal-title":"Nat Med"},{"key":"R22-20260422","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","article-title":"Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study.","volume":"35","author":"Hsu","year":"2017","journal-title":"J Clin Oncol"},{"key":"R23-20260422","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1200\/JCO.2017.35.15_suppl.6025","article-title":"An open-label, multicohort, phase I\/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): efficacy and safety in recurrent or metastatic (R\/M) nasopharyngeal carcinoma (NPC).","volume":"35","author":"Delord","year":"2021","journal-title":"J Clin Oncol"},{"key":"R24-20260422","doi-asserted-by":"crossref","first-page":"104640","DOI":"10.1016\/j.oraloncology.2020.104640","article-title":"The efficacy and safety of PD-1\/PD-L1 inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis.","volume":"104","author":"Wang","year":"2020","journal-title":"Oral Oncol"},{"key":"R25-20260422","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.pedhc.2021.04.011","article-title":"PRISMA 2020: an update.","volume":"35","author":"Swartz","year":"2021","journal-title":"J Pediatr Health Care"},{"key":"R26-20260422","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4103\/0253-7184.69003","article-title":"Formulating a researchable question: a critical step for facilitating good clinical research.","volume":"31","author":"Aslam","year":"2010","journal-title":"Indian J Sex Transm Dis AIDS"},{"key":"R27-20260422","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00005344-198503000-00021","article-title":"The effects of milrinone on action potential characteristics, conduction, automaticity, and reflected reentry in isolated myocardial fibers.","volume":"7","author":"Davidenko","year":"1985","journal-title":"J Cardiovasc Pharmacol"},{"key":"R29-20260422","doi-asserted-by":"crossref","first-page":"106723","DOI":"10.1016\/j.oraloncology.2024.106723","article-title":"Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma (COMPASSION-06): a phase II multicenter study.","volume":"151","author":"Chen","year":"2024","journal-title":"Oral Oncol"},{"key":"R30-20260422","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","article-title":"Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.","volume":"19","author":"Fang","year":"2018","journal-title":"Lancet Oncol"},{"key":"R31-20260422","doi-asserted-by":"crossref","first-page":"648637","DOI":"10.3389\/fonc.2021.648637","article-title":"The effect of prolonged duration of intensity modulated radiotherapy for nasopharyngeal carcinoma.","volume":"11","author":"Hua","year":"2021","journal-title":"Front Oncol"},{"key":"R32-20260422","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","article-title":"Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo Clinic Phase 2 Consortium (NCI-9742).","volume":"36","author":"Ma","year":"2018","journal-title":"J Clin Oncol"},{"key":"R33-20260422","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.21873\/invivo.12127","article-title":"Investigation of the efficacy and safety of nivolumab in recurrent and metastatic nasopharyngeal carcinoma.","volume":"34","author":"Sato","year":"2020","journal-title":"In Vivo"},{"key":"R34-20260422","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1200\/JCO.20.02712","article-title":"Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02).","volume":"39","author":"Wang","year":"2021","journal-title":"J Clin Oncol"},{"key":"R35-20260422","doi-asserted-by":"crossref","first-page":"e003790","DOI":"10.1136\/jitc-2021-003790","article-title":"Efficacy, safety, and biomarker analysis of camrelizumab in previously treated recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN study).","volume":"9","author":"Yang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R36-20260422","doi-asserted-by":"crossref","first-page":"201","DOI":"10.21037\/atm.2018.05.14","article-title":"The efficacy of first-line chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis.","volume":"6","author":"Ma","year":"2018","journal-title":"Ann Transl Med"},{"key":"R37-20260422","doi-asserted-by":"crossref","first-page":"S786","DOI":"10.1016\/j.annonc.2021.08.1268","article-title":"858O Results of KEYNOTE-122: a phase III study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R\/M) nasopharyngeal carcinoma (NPC).","volume":"32","author":"Chan","year":"2021","journal-title":"Ann Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047828","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T06:00:40Z","timestamp":1776837640000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047828","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"2025-07-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}